Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 1Colonic Neoplasms 1Adenocarcinoma of the Lower Rectum 1Adenocarcinoma 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9Paclitaxel 8pembrolizumab 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Albumin-Bound Paclitaxel 6Pemetrexed 4Nivolumab 4Irinotecan 4Everolimus 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2vosaroxin 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × XELOX × Clear all
NCT00127036 2017-03-23

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
65 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡